Clin2
NCT07188285Possibly a fitEnrolling by invitation

Immune system study for active autoimmune diseases

Systemic Lupus ErthematosusSjogren's SyndromeInflammatory MyopathiesSystemic Sclerosis (SSc)VasculitisRheumatoid Arthritis (RA)Ankylosing SpondylitisOsteoarthritis

Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism, Immune system & allergy, Skin clinical trials.

This study uses a blood test called mass spectrometry to look at the immune system in people with active autoimmune diseases. It aims to find patterns that could help doctors better understand and treat these conditions.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
500 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are between 18 and 70 years old.
  • You have been diagnosed with one of these autoimmune diseases: lupus, Behcet's, vasculitis, rheumatoid arthritis, ankylosing spondylitis, Sjogren's, myositis, scleroderma, psoriatic arthritis, or gout.
  • Your disease is currently active (not in remission).
  • You are taking prednisone ≤1 mg/kg/day or another steroid at an equivalent dose, and you may be taking disease-modifying drugs like methotrexate or hydroxychloroquine.
  • You have not used certain biologics (like rituximab) in the last 6 months, or other biologics in the last 3 months, and you have not had high-dose steroids or IVIg/cyclophosphamide recently.
  • You do not have serious infections, heart failure, kidney or liver problems, active cancer, or HIV/hepatitis C.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06980597Recruiting· Phase 1
Testing OL-108 for active autoimmune diseases

This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.

Beijing
NCT06888960Recruiting· Early Phase 1
Testing CC312 for people with autoimmune diseases

This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.

Tianjin, China
NCT07150000Recruiting
Rheumatic disease research study for patients and healthy volunteers

This study is for people with certain rheumatic conditions (like arthritis, lupus, or vasculitis) and for healthy volunteers. It aims to learn more about these diseases and improve how they are treated.

Bonn, North Rhine-Westphalia
NCT06587828Recruiting
Looking at immune cells in people with autoimmune disease

This study collects blood, tissue, and other samples from people with autoimmune diseases like Crohn's disease, multiple sclerosis, or lupus. Researchers will study your immune cells (T cells) to learn what they are attacking, which could lead to better treatments in the future.

Orange, California
NCT06778343Recruiting
Biomarkers study for inflammatory rheumatic diseases

This study is looking for people with ankylosing spondylitis, rheumatoid arthritis, or lupus to help find biomarkers that may make diagnosis easier. If you have one of these conditions and haven't tried biologic therapies, you may be able to join.

Lisbon
NCT05251415Recruiting
Study of rare autoimmune diseases with blood and medical samples

This trial collects clinical and lab information (like blood and medical history) from people with rare autoimmune diseases, especially when symptoms are unusual. It aims to better understand what causes these illnesses and how newer treatments may help.

Toulouse

Hear when a new Systemic Lupus Erthematosus trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.